Carbon dioxide removal added to breathing support for severe COPD flare-ups
Tests adding blood carbon dioxide removal to noninvasive ventilation in adults with severe COPD worsening.
Plain-language title generated from the registry record
Registry title: Extracorporeal Carbon Dioxide Removal Plus Noninvasive Ventilation in Patients With COPD Not Eligible for Intubation
Key facts
- Where
- Barcelona, SpainSee the site
Where in Spain
- Hospital del MarBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital del Mar Research Institute (IMIM)
- Trial code
- NCT07785375
- Record updated
- 25 August 2026
- Original description
This study will evaluate whether adding extracorporeal carbon dioxide removal (ECCO2R) to noninvasive ventilation can improve breathing in adults hospitalized with a severe worsening of chronic obstructive pulmonary disease (COPD). Participants will have high carbon dioxide levels and increased acidity in their blood despite treatment with noninvasive ventilation and will not be eligible for invasive mechanical ventilation through a breathing tube.Read full original descriptionShow less
Randomized Clinical Trial of the Efficacy of Extracorporeal Carbon Dioxide Removal and Noninvasive Ventilation in Patients With COPD Not Eligible for Endotracheal Intubation
This study will evaluate whether adding extracorporeal carbon dioxide removal (ECCO2R) to noninvasive ventilation can improve breathing in adults hospitalized with a severe worsening of chronic obstructive pulmonary disease (COPD). Participants will have high carbon dioxide levels and increased acidity in their blood despite treatment with noninvasive ventilation and will not be eligible for invasive mechanical ventilation through a breathing tube.
A total of 14 participants will be assigned by chance to receive either noninvasive ventilation alone or noninvasive ventilation together with ECCO2R. ECCO2R removes carbon dioxide directly from the blood through a catheter placed in a large vein. The main aim is to determine whether adding ECCO2R reduces the breathing rate within 4 hours. The study will also assess blood carbon dioxide and acidity, duration of noninvasive ventilation, length of hospital stay, survival, and complications related to ECCO2R.
Inclusion: Age 18 years or older; Confirmed diagnosis of chronic obstructive pulmonary disease (COPD); Acute exacerbation of COPD, defined as increased dyspnea, cough, and/or sputum production; Acute hypercapnic respiratory failure requiring noninvasive ventilation, with arterial pH <7.30 and PaCO2 >50 mmHg; Not eligible for endotracheal intubation because of a medical decision or the participant's prior decision; Persistent respiratory acidosis, defined as arterial pH <7.30 with PaCO2 >45 mmHg, after 4 hours of noninvasive ventilation.
Exclusion: Contraindication to extracorporeal carbon dioxide removal due to a coagulation disorder; Inability to establish adequate vascular access.